HP
ALGS icon

Harbourvest Partners’s Aligos Therapeutics ALGS Stock Holding History

Harbourvest Partners’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-751
Closed -$6.57K – 36
2024
Q2 		$6.57K Hold
751
– – ﹤0.01% 39
2024
Q1 		$18.4K Hold
751
– – 0.01% 47
2023
Q4 		$12.5K Hold
751
– – ﹤0.01% 52
2023
Q3 		$14K Hold
751
– – ﹤0.01% 57
2023
Q2 		$18.2K Hold
751
– – 0.01% 57
2023
Q1 		$16.4K Hold
751
– – 0.01% 62
2022
Q4 		$17.9K Hold
751
– – 0.01% 64
2022
Q3 		$21K Hold
751
– – 0.01% 67
2022
Q2 		$23K Hold
751
– – 0.01% 62
2022
Q1 		$40K Hold
751
– – 0.01% 66
2021
Q4 		$223K Hold
751
– – 0.03% 62
2021
Q3 		$291K Hold
751
– – 0.03% 49
2021
Q2 		$383K Buy
+751
New +$479K 0.04% 41

Other funds holding ALGS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Harbourvest Partners's ALGS Position: Q3 2024 in Review

Harbourvest Partners sold out of Aligos Therapeutics (ALGS) in Q3 2024, closing a stake of 751 shares — an estimated $6.57K sold.

Harbourvest Partners first reported a position in ALGS in Q2 2021 and held it in 13 quarters. The position peaked at $383K in Q2 2021. 27 funds tracked by Wall St. Rank hold ALGS as of Q3 2024.

  • Harbourvest Partners reported no remaining Aligos Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Harbourvest Partners sold 751 Aligos Therapeutics shares in Q3 2024, an estimated $6.57K.
  • Harbourvest Partners first reported a position in Aligos Therapeutics in Q2 2021 and held it in 13 quarters.
  • Harbourvest Partners's Aligos Therapeutics position peaked at $383K in Q2 2021.
  • 27 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2024.

Based on Harbourvest Partners's 13F filing for Q3 2024, filed 14 Nov 2024.